Results 331 to 340 of about 66,239 (358)
Some of the next articles are maybe not open access.
Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome
Annals of Internal Medicine, 2019Antiphospholipid antibody syndrome (APS) is an acquired thrombophilic disorder in which vascular thrombosis (venous or arterial) and pregnancy losses may occur in the presence of persistent antiphospholipid antibodies (aPLs) (14).
J. Ordi‐Ros +10 more
semanticscholar +1 more source
[Rivaroxaban: clinical pharmacology].
Annales francaises d'anesthesie et de reanimation, 2009Rivaroxaban (Xarelto) is a new oral, direct and selective inhibitor of the factor Xa of the coagulation cascade. The main pharmacokinetic characteristics of rivaroxaban are a bioavailability of approximately 80-100%, a maximum concentration obtained in 2 to 4 hours, a terminal half-life of elimination of 7 to 11 hours, a renal elimination for 1/3 for ...
Mismetti, P., Laporte, S.
openaire +2 more sources
Rivaroxaban for Thromboprophylaxis
New England Journal of Medicine, 2008Giuseppe Lippi +2 more
openaire +2 more sources
Rivaroxaban versus Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial.
Chest, 2021B. Planquette +24 more
semanticscholar +1 more source
Rivaroxaban, ticagrelor, and fidaxomicin
Journal of the American Pharmacists Association, 2011Daniel A. Hussar, Amanda F. Schartel
openaire +3 more sources
Is rivaroxaban an all-rounder?
International Journal of Cardiology, 2023Can, Xu, Jun, Meng
openaire +2 more sources
Oral Rivaroxaban for Pulmonary Embolism
New England Journal of Medicine, 2012Niamh M O'Connell +2 more
openaire +5 more sources